| 10/26 | PRESS RELEASE : Novartis delivers solid Q3 results, with strong growth in Innovative Medic.. | DJ |
| 10/21 | INSIDER SELL : Beigene | MT |
| 10/21 | BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatme.. | PU |
| 10/21 | BEIGENE : Russia Approves BeiGene's Cancer Medicine for Treatment of Mantle Cell Lymphoma | MT |
| 10/20 | BEIGENE : Brukinsa Gets Russian Approval to Treat Certain Patients With Mantle Cell Lympho.. | MT |
| 10/20 | BEIGENE : and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatme.. | BU |
| 10/20 | Beigene and Nanolek Announce Approval in Russia for Brukinsa? (Zanubrutinib) for Treatm.. | CI |
| 10/14 | BEIGENE : SVB Leerink Adjusts Price Target on BeiGene to $414 From $417, Maintains Outperf.. | MT |
| 10/14 | BeiGene, Ltd. Provides Contract Update with Celgene Logistics Sàrl | CI |
| 10/13 | BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) fo.. | PU |
| 10/12 | BEIGENE : Bernstein Starts BeiGene at Outperform With $431 Price Target | MT |
| 10/11 | BEIGENE : Brukinsa Approved in Australia for Mantle Cell Lymphoma | MT |
| 10/10 | BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mant.. | CI |
| 10/10 | BEIGENE : Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantl.. | BU |
| 10/10 | BEIGENE : Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantl.. | BU |
| 10/08 | BEIGENE : Drug for Waldenstrom's Macroglobulinemia Wins Regulatory Nod in Australia | MT |
| 10/07 | BEIGENE : Brukinsa Approved in Australia for Waldenstrom's Macroglobulinemia | MT |
| 10/07 | BEIGENE : Announces First Regulatory Approval in Australia for BRUKINSA® (Zanubrutinib) fo.. | BU |
| 10/07 | Beigene, Ltd. Announces First Regulatory Approval in Australia for Brukinsa for Treatme.. | CI |
| 09/24 | LEAP THERAPEUTICS : Raises $104 Million After Completing Securities Offering; Stock Rises | MT |
| 09/23 | INSIDER SELL : Beigene | MT |
| 09/21 | BEIGENE : Added to FTSE Russell Indices | MT |
| 09/20 | BEIGENE : European commercial team is preparing to launch BRUKINSA, the company's first me.. | PU |
| 09/20 | BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment o.. | CI |
| 09/20 | BEIGENE : Wins Positive Opinion from Europe's Drug Regulator for Waldenstrom's Macroglobul.. | MT |
| 09/20 | BEIGENE : Announces Inclusion in FTSE Russell Indices | BU |
| 09/20 | BEIGENE, LTD.(SEHK : 6160) added to FTSE All-World Index | CI |
| 09/17 | Asian ADRs Move Lower in Friday Trading | MT |
| 09/17 | US Futures Modestly Lower Ahead of Fed Meeting Next Week | MT |
| 09/17 | BEIGENE : Receives Positive Opinion for Brukinsa by European Medicines Agency; Shares Clim.. | MT |
| 09/17 | Top Premarket Gainers | MT |
| 09/17 | BEIGENE : Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment of.. | BU |
| 09/17 | BeiGene Receives Positive CHMP Opinion for BRUKINSA® (Zanubrutinib) for the Treatment o.. | CI |
| 09/17 | BeiGene Gets CHMP Backing of Brukinsa in Waldenstrom's Macroglobulinemia | DJ |
| 09/16 | Health Care Stocks Largely Sitting Out Markets Recovery This Afternoon | MT |
| 09/16 | Health Care Stocks Falling Thursday Afternoon | MT |
| 09/16 | INSIDER SELL : Beigene | MT |
| 09/16 | LEAP THERAPEUTICS : Says Additional Data from Mid-Stage Study Show Potential of Cancer Com.. | MT |
| 09/16 | BEIGENE : US FDA Grants BeiGene Accelerated Approval for Marginal Zone Lymphoma Treatment | MT |
| 09/15 | China's biotech sector comes of age with big licensing deals, global ambitions | RE |
| 09/15 | BEIGENE : With its second internally developed medicine filed outside China, BeiGene furth.. | PU |
| 09/15 | Health Care Stocks Edge Higher Premarket Wednesday | MT |
| 09/15 | BEIGENE : Says US FDA Grants it Accelerated Approval for Brukinsa for Relapsed or Refracto.. | MT |
| 09/15 | BEIGENE : U.S. FDA Grants BRUKINSA® (Zanubrutinib) Accelerated Approval in Relapsed or Ref.. | BU |
| 09/15 | BeiGene, Ltd. announces U.S. Food and Drug Administration Grants Brukinsa Approval in R.. | CI |
| 09/14 | INSIDER BUY : Beigene | MT |
| 09/13 | Leap Therapeutics Sees Positive Data for Trial of Cancer Treatment | DJ |
| 09/13 | BEIGENE : US FDA Accepts BeiGene's Biologics License Application for Cancer Drug; Shares J.. | MT |
| 09/13 | BEIGENE : Says US FDA Accepts Biologics License Application for Cancer Drug Tislelizumab | MT |
| 09/13 | BEIGENE : Announces U.S. FDA Acceptance of Biologics License Application for Tislelizumab .. | BU |
| 09/13 | BeiGene, Ltd. Announces U.S. FDA Acceptance of Biologics License Application for Tislel.. | CI |
| 09/12 | BEIGENE : to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 2021 | BU |
| 09/12 | BeiGene to Present Latest Findings in Robust Lung Cancer Portfolio at ESMO Congress 202.. | CI |
| 09/03 | BEIGENE : Grants Share Options to Four Employees | MT |
| 09/02 | BEIGENE : This marks the second FDA approval for BRUKINSA and its third approval in Walden.. | PU |
| 09/02 | HANG SENG : Hong Kong Stocks Finish Slightly Higher; BeiGene Rises 5% | MT |
| 09/02 | BEIGENE : US FDA Approves BeiGene's Cancer Medicine as Treatment for Rare Lymphoma; Shares.. | MT |
| 09/01 | BEIGENE : Brukinsa Gets FDA Nod for Treatment of Waldenstrom's Macroglobulinemia | MT |
| 09/01 | BEIGENE : U.S. FDA Grants BRUKINSA® (Zanubrutinib) Approval in Waldenström's Macroglobulin.. | BU |
| 09/01 | BeiGene, Ltd. Receives Approval from the U.S. Food and Drug Administration of BRUKINSA®.. | CI |
| 08/30 | Asian ADRs Move Lower in Monday Trading | MT |
| 08/30 | BEIGENE : H1 Loss Narrows, Revenue Climbs on Increased Income From Products, Collaboration.. | MT |
| 08/26 | HUTCHMED CHINA : BeiGene Start US Clinical Trial of Combination Therapy for Breast Cancer | MT |
| 08/26 | HUTCHMED CHINA : Doses First Patient in Study of Potential Drug for Breast, Endometrial Ca.. | MT |
| 08/26 | HUTCHMED CHINA : Launches Early-Stage Study of Cancer Combo Therapy in US | MT |
| 08/24 | BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo.. | PU |
| 08/23 | BEIGENE : Says Chinese Regulator Accepts Supplemental Biologics License Application for Ca.. | MT |
| 08/23 | BeiGene Announces Acceptance of a Supplemental Biologics License Application in China f.. | CI |
| 08/22 | BEIGENE : Announces Acceptance of a Supplemental Biologics License Application in China fo.. | BU |
| 08/19 | BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA® (Dinutuximab Beta) for .. | PU |
| 08/18 | BEIGENE : and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for P.. | AQ |
| 08/18 | BEIGENE : Swiss Regulator Begins Review of BeiGene's Marketing Application for Lymphoma Dr.. | MT |
| 08/18 | BEIGENE : Announces Acceptance by Swissmedic of Marketing Authorization Application for BR.. | BU |
| 08/18 | BeiGene Announces Acceptance by Swissmedic of Marketing Authorization Application for B.. | CI |
| 08/17 | BEIGENE : UK Partner's Cancer Drug Gets Conditional Approval in China | MT |
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
